Lori Hazlehurst - Publications

Biology (Cell Biology, Microbiology, Molecular Biology) University of South Florida, Tampa, FL, United States 
Oncology, Cell Biology, Pharmacology

52 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leukemia Research. 74: 89-96. PMID 30340199 DOI: 10.1016/j.leukres.2018.10.002  0.32
2017 Emmons MF, Anreddy N, Cuevas J, Steinberger K, Yang S, McLaughlin M, Silva A, Hazlehurst LA. MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma. Scientific Reports. 7: 2685. PMID 28578393 DOI: 10.1038/s41598-017-02713-0  0.48
2017 Li X, Nelson CG, Nair RR, Hazlehurst L, Moroni T, Martinez-Acedo P, Nanna AR, Hymel D, Burke TR, Rader C. Stable and Potent Selenomab-Drug Conjugates. Cell Chemical Biology. PMID 28330604 DOI: 10.1016/j.chembiol.2017.02.012  0.48
2015 Shay G, Hazlehurst L, Lynch CC. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. Journal of Molecular Medicine (Berlin, Germany). PMID 26423531 DOI: 10.1007/s00109-015-1345-4  0.48
2015 Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH. Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene. PMID 26387544 DOI: 10.1038/onc.2015.334  0.48
2014 Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS. A preclinical assay for chemosensitivity in multiple myeloma. Cancer Research. 74: 56-67. PMID 24310398 DOI: 10.1158/0008-5472.CAN-13-2397  0.48
2013 Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM. CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. Journal of Cancer. 4: 614-25. PMID 24155773 DOI: 10.7150/jca.7080  0.48
2013 Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA. MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma. Molecular Cancer Therapeutics. 12: 2446-58. PMID 24048737 DOI: 10.1158/1535-7163.MCT-13-0310  0.48
2013 Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. The one-two punch: combination treatment in chronic myeloid leukemia. Critical Reviews in Oncology/Hematology. 88: 667-79. PMID 23969231 DOI: 10.1016/j.critrevonc.2013.07.017  0.48
2013 Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. Journal of Medicinal Chemistry. 56: 3768-82. PMID 23600925 DOI: 10.1021/jm301234k  0.48
2012 Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA. Emerging strategies for targeting cell adhesion in multiple myeloma. Advances in Pharmacology (San Diego, Calif.). 65: 143-89. PMID 22959026 DOI: 10.1016/B978-0-12-397927-8.00006-3  0.48
2012 Nair RR, Tolentino JH, Hazlehurst LA. Role of STAT3 in Transformation and Drug Resistance in CML. Frontiers in Oncology. 2: 30. PMID 22649784 DOI: 10.3389/fonc.2012.00030  0.48
2012 Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA. Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leukemia Research. 36: 756-63. PMID 22209738 DOI: 10.1016/j.leukres.2011.12.002  0.48
2011 Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype. Molecular Cancer Therapeutics. 10: 2257-66. PMID 21980133 DOI: 10.1158/1535-7163.MCT-11-0149  0.48
2011 Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, et al. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Molecular & Cellular Proteomics : McP. 10: M110.005520. PMID 21846842 DOI: 10.1074/mcp.M110.005520  0.48
2011 Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, et al. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics. Clinical Applications. 5: 383-96. PMID 21656910 DOI: 10.1002/prca.201000115  0.48
2011 Yanamandra N, Buzzeo RW, Gabriel M, Hazlehurst LA, Mari Y, Beaupre DM, Cuevas J. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. The Journal of Pharmacology and Experimental Therapeutics. 337: 636-43. PMID 21378206 DOI: 10.1124/jpet.110.172809  0.48
2011 Padron E, Hazlehurst LA, Pinilla-Ibarz J. Molecular Pathogenesis of BCR-ABL in Chronic Myeloid Leukemia Advances in Malignant Hematology. 62-70. DOI: 10.1002/9781444394016.ch4  0.48
2010 Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochemical Pharmacology. 80: 602-12. PMID 20382130 DOI: 10.1016/j.bcp.2010.04.003  0.48
2009 Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Research. 69: 9367-75. PMID 19934314 DOI: 10.1158/0008-5472.CAN-09-2616  0.48
2009 Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Research. 69: 6899-905. PMID 19690141 DOI: 10.1158/0008-5472.CAN-09-0484  0.48
2009 Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, Wang HG, Dalton WS, Hazlehurst LA. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Molecular Cancer Therapeutics. 8: 2441-51. PMID 19671765 DOI: 10.1158/1535-7163.MCT-09-0113  0.48
2009 Hazlehurst LA. Detection of DNA damage induced by topoisomerase II inhibitors, gamma radiation and crosslinking agents using the comet assay. Methods in Molecular Biology (Clifton, N.J.). 523: 169-76. PMID 19381939 DOI: 10.1007/978-1-59745-190-1_12  0.48
2009 Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control : Journal of the Moffitt Cancer Center. 16: 100-7. PMID 19337196  0.48
2009 Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Research. 69: 1009-15. PMID 19155309 DOI: 10.1158/0008-5472.CAN-08-2419  0.48
2009 Hazlehurst L, Hacker M. Drug Resistance Pharmacology. 371-385. DOI: 10.1016/B978-0-12-369521-5.00015-4  0.48
2008 Kamath V, Goldgof D, Argilagos R, Hazlehurst L, Eschrich S. Towards a framework for analysis of biophotonic images of mouse models of cancer. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2008: 3079-82. PMID 19163357 DOI: 10.1109/IEMBS.2008.4649854  0.48
2008 Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular Cancer Therapeutics. 7: 3169-75. PMID 18852120 DOI: 10.1158/1535-7163.MCT-08-0314  0.48
2008 Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Proteomic contributions to personalized cancer care. Molecular & Cellular Proteomics : McP. 7: 1780-94. PMID 18664563 DOI: 10.1074/mcp.R800002-MCP200  0.48
2008 Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2519-26. PMID 18451212 DOI: 10.1158/1078-0432.CCR-07-2223  0.48
2007 Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 110: 1631-8. PMID 17502456 DOI: 10.1182/blood-2006-11-060350  0.48
2007 Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 21: 1521-31. PMID 17476277 DOI: 10.1038/sj.leu.2404723  0.48
2007 Hazlehurst LA, Argilagos RF, Dalton WS. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. British Journal of Haematology. 136: 269-75. PMID 17233818 DOI: 10.1111/j.1365-2141.2006.06435.x  0.48
2006 Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 108: 3881-9. PMID 16917002 DOI: 10.1182/blood-2005-10-009084  0.48
2006 Emmons M, Boulware D, Sullivan DM, Hazlehurst LA. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death. Biochemical Pharmacology. 72: 11-8. PMID 16678798 DOI: 10.1016/j.bcp.2006.03.017  0.48
2006 Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Research. 66: 2338-45. PMID 16489039 DOI: 10.1158/0008-5472.CAN-05-3256  0.48
2005 Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 106: 698-705. PMID 15802532 DOI: 10.1182/blood-2004-11-4286  0.48
2004 Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies. Seminars in Hematology. 41: 1-5. PMID 15190509  0.48
2004 Engel R, Valkov NI, Gump JL, Hazlehurst L, Dalton WS, Sullivan DM. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Experimental Cell Research. 295: 421-31. PMID 15093741 DOI: 10.1016/j.yexcr.2004.01.012  0.48
2003 Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Research. 63: 7900-6. PMID 14633719  0.48
2003 Hazlehurst LA, Landowski TH, Dalton WS. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene. 22: 7396-402. PMID 14576847 DOI: 10.1038/sj.onc.1206943  0.48
2001 Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Reviews. 20: 43-50. PMID 11831646 DOI: 10.1023/A:1013156407224  0.48
2001 Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 4262-71. PMID 11751528  0.48
2001 Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 98: 1897-903. PMID 11535527 DOI: 10.1182/blood.V98.6.1897  0.48
2001 Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia. 15: 1232-9. PMID 11480565 DOI: 10.1038/sj.leu.2402179  0.48
2000 Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 19: 4319-27. PMID 10980607 DOI: 10.1038/sj.onc.1203782  0.48
2000 Hazlehurst LA, Wisner L, Storey JA, Sullivan DM, Dalton WS. Adhesion of U937 CELLS to fibronectin via βl integrins confers resistance to topoisomeraseii inhibitors and correlates with decreased DNA double strand breaks and topoisomerase Hβ activity Blood. 96.  0.48
1999 Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, Dalton WS. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Research. 59: 1021-8. PMID 10070958  0.48
1999 Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 93: 1658-67. PMID 10029595  0.48
1998 Hazlehurst LA, Gros P, Dalton WS. Chromosome mediated gene transfer of drug resistance to mitoxantrone. Anticancer Research. 18: 1005-10. PMID 9615755  0.48
1995 Hazlehurst LA, Krapcho AP, Hacker MP. Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: Aza-anthracenediones Cancer Letters. 91: 115-124. PMID 7750086 DOI: 10.1016/0304-3835(95)91035-5  0.48
1995 Hazlehurst LA, Krapcho AP, Hacker MP. Comparison of AZA-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells Biochemical Pharmacology. 50: 1087-1094. PMID 7575665 DOI: 10.1016/0006-2952(95)00246-V  0.48
Show low-probability matches.